Trial Profile
Second-line pemetrexed + oxaliplatin vs pemetrexed + cisplatin in patients with advanced erlotinib-refractory non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Nov 2013
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Pemetrexed (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Nov 2013 New trial record